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Background: Multiple sclerosis (MS) is an inflammatory disease where many of the patients suffer from spasticity
impacting their quality-of-life. The purpose of this paper was to linguistically validate and psychometrically test
the Multiple Sclerosis Spasticity Scale (MSSS-88) in German speaking MS patients.
Methods: The study had two stages: 1) forward/backward translations of the original MSSS-88 scale into German,
discussions with MS-experts and cognitive debriefings with MS patients; 2) psychometric evaluation of the German
version. Data collection took part in an observational multi-centre study in Germany (MOVE2).
Results: The German translation of the MSSS-88 scale was discussed with three MS-experts; followed by two
cognitive debriefing sessions with 12 MS patients. For psychometric evaluation the MSSS-88 was filled in by 87 MS
patients with a mean age of 50.2 ± 10.4 years; 26.4% of them had severe spasticity. Data quality was acceptable.
Missing data for items of the MSSS-88 were low (range 0–5.75%). Psychometric testing of the MSSS-88 revealed
excellent values for reliability and validity. Significant differences between groups regarding severity, grading, type
and self-ratings of MS-spasticity and sleep disturbances were found. Sensitivity to change could be demonstrated
for the MSSS-88 in the group of MS patients treated with cannabinoid oromucosal spray vs. non-treated patients.
In the treated group significant changes with a moderate effect size were found for ‘muscle spasms’, ‘emotional
health’ and ‘pain/discomfort’. No significant changes could be detected in the non-treated group.
Conclusion: Preliminary evidence from this small study supports reliability, validity, and responsiveness of the
German version of the MSSS-88 for measuring the impact of spasticity in MS.
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Multiple sclerosis (MS) is an inflammatory disease of the
brain and spinal cord resulting in neurological dysfunction
[1]. MS-symptoms can occur in episodic attacks (relapsing
form), or gradually accumulate over time (progressive
form), or in a combination of both [2]. MS patients typic-
ally suffer from the following neurological symptoms or
signs: changes in sensation (e.g. loss of sensitivity, tingling,
pricking or numbness), muscle weakness, muscle spasms,* Correspondence: s.mackensen@uke.uni-hamburg.de
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unless otherwise stated.difficulties in mobility and coordination, visual, speech
and swallowing problems, bladder and bowel distur-
bances, or pain; in addition, fatigue, cognitive impairments
and affective symptoms may also often occur [3-7]. Up to
90% of MS patients suffer from spasticity [8], which
can be defined as “a motor disorder characterized by
a velocity-dependent increase in tonic stretch reflexes
(muscle tone) with exaggerated tendon jerks resulting
from hyperexcitability of the stretch reflex as one compo-
nent of upper motor neuron syndrome” [9]. MS patients
refer to spasticity-related symptoms using a range of terms
including muscle rigidity, sudden jerks or contractions in
limbs or trunk often associated with pain [10]. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of the disease [11]. Spasticity can significantly affect motor
performance, activities of daily living, and well-being
[12-14]. It can be measured via electrophysiological, bio-
mechanical and clinical evaluation [15]. For clinical evalu-
ation of the severity of spasticity in MS the (Modified)
Ashworth scale remains the most widely used by health
specialists [16,17], together with the categorical severity
scale (mild/moderate/severe) [18]. Recently the patient-
reported numeric rating scale (NRS) has been used
for the subjective assessment of the severity of spasti-
city from the patient’s perspective [19,20]. Progression
of disability and severity of impairment in MS patients
can be measured with the Expanded Disability Status
Scale (EDSS) [21,22], which is recommended in the
German guideline for use in clinical-neurological examin-
ation of MS [23].
In the last decades, there has been a growing interest
in including patient-reported outcomes (PROs) in medical
research [24]. Several disease-specific PRO instruments
assessing the impact of the disease on MS patients have
been developed in recent years. An overview of validated in-
struments is given in a review paper by Opara et al. [25]. Re-
cently, the Multiple Sclerosis Spasticity Scale (MSSS-88)
has been developed with the aim of constructing a self-
assessment instrument to measure patients’ perception
and experiences of the impact of spasticity due to MS. It
was developed to have an additional instrument to exist-
ing neurophysiological, clinical and biomedical techniques
lacking to measure the broader consequences of spasticity
for the patient. The MSSS-88 scale consists of 88 items
pertaining to 8 domains: ‘muscle stiffness’, ‘pain/discom-
fort’, ‘muscle spasms’, ‘activities of daily living’ (ADL), ‘walk-
ing’, ‘body movements’, ‘emotional health’ and ‘social
functioning’. Each item is rated on a 4-point scale with
answers from 1 (‘not at all bothered’) to 4 (‘extremely
bothered’) [26]. Subscale values are transformed from 0-
100 with high scores indicating high impairment allowing
comparison across subscales. The MSSS-88 provided solid
psychometric properties in the study sample, but was only
available in English up to now. To use the MSSS-88
in German patients, linguistic validation is necessary.
Linguistic validation and cross-cultural adaptation of
PRO instruments should follow established procedures
[27-29], which are based on the translation (including
forward translation, reconciliation, back translation and
cognitive debriefing) of the original language into a target
language, followed by the psychometric testing of the
instrument in the new population.
The aim of this project was to linguistically validate
and cross-culturally adapt the original MSSS-88 ques-
tionnaire from English into German for the use in
German speaking MS patients with spasticity and
testing its psychometric characteristics.Patients and methods
Design
The study had two stages including 1) the development
of the MSSS-88 German version, and 2) data collection
in German MS patients and psychometric evaluation.
Stage 1: Development of the MSSS-88 German version
The MSSS-88 was translated from English into German
by two independent translators experienced in medical
translation. Differences in the two resulting versions
were discussed with a MS-expert and reconciled by two
members of the study group (SvM, CP). After back-
translation of the consensus version by one independent
translator, the original MSSS-88 English scale and the
English back-translation were compared. Three MS-experts
were asked to discuss phrasing and content of all items.
Suggestions were implemented and the modified German
version was discussed with MS patients in two cognitive
debriefing (CD) sessions (four and eight patients, infor-
med consent prior to CD). MS experts and MS patients
discussed each item and gave recommendations for lin-
guistic improvement or rewording of unclear items. Items
which caused problems (e.g. ambiguity, wording) were
discussed with two of the developers of the original
MSSS-88 scale (J.C. Hobart, A. Riazi) to ensure the ori-
ginal item concepts were maintained and to clarify unclear
aspects.
Stage 2: Psychometric evaluation
For the psychometric evaluation (PE) of the MSSS-88 we
had the chance to include und test the new German trans-
lation of the MSSS-88 in the frame of the German-wide
multicentre, prospective, observational, non-interventional
MOVE2 study (Mobility Improvement in MS patients
with spasticity) [30] as an ancillary study in a subset of the
enrolled MS patients. The study was approved by the
Landesärztekammer (State Medical Association) Baden-
Württemberg and the ethics committee of the medical
faculty of the University of Rostock in Germany. The aim
of the MOVE2 study was to evaluate the clinical outcomes
and safety of a cannabinoid oromucosal spray in the real-
life setting after its launch in Germany.
Study centers and patients
A total number of 10 out of the 42 participating study
centers from the MOVE2 study (office-based neurologists,
MS outpatient clinics, rehabilitation centres, neurological
hospitals) were asked to recruit at least 10 eligible MS pa-
tients with spasticity resulting in a planned total sample of
100 MS patients (1/3 mild, 1/3 moderate, 1/3 severe).
Additional patients with mild spasticity were recruited in
order to include the full range of patients beyond the in-
clusion criteria of the MOVE2 study. A formal sample size
calculation was not carried out prior to the study. The
Henze et al. Health and Quality of Life Outcomes 2014, 12:119 Page 3 of 12
http://www.hqlo.com/content/12/1/119sample size was informed by sample sizes used in pub-
lished validation studies as well as based on the availability
and eligibility of patients in the study centers of the
MOVE2 study who were willing to participate. Patients
were eligible when they had fulfilled the following inclu-
sion criteria: age ≥18 years, MS-diagnosis with mild, mod-
erate or severe spasticity (severity was rated by the
physician, defined as whenever spasticity causes limita-
tions to ADL, activities in a social environment or where
there is a danger of spasticity-related complications), pa-
tient’s informed consent. No restriction was done related
to spasticity treatment. Exclusion criteria were: spasticity
due to other causes than MS, patients with relevant
cognitive impairment due to physicians’ judgment or
deficits of the German language. Patients were con-
secutively recruited by the participating physicians
due to the point of time of their regular visit and
when they met the inclusion criteria. Some of the
participating patients started treatment with an oromuco-
sal cannabinoid spray as add-on therapy to their already
existing antispastic drug therapy if their spasticity was
moderate to severe and they had further existing spasticity
symptoms.
Data collection
Patients filled in the MSSS-88 scale together with other
PRO measures; clinical data were collected from physi-
cians. Patients filled in the questionnaires twice (at inclu-
sion visit and as a postal data collection after one month
(FU1)), including demographic and clinical characteristics
as well as validated instruments assessing HRQoL with
the generic EQ-5D-3L (five domains: ‘mobility’, ‘self care’,
‘usual activities’, ‘pain/discomfort’, ‘anxiety/depression’)
[31,32] and the MS-specific MSQoL-54 (consisting of
54 items pertaining to 12 subscales and two composite
scores: ‘physical health’, ‘mental health’) [33,34]. Patients
rated the degree of spasticity on the 11 point (0 to 10)
NRS [19] and filled in the German “Würzburger Fatigue
Inventory for MS” (WEIMuS), consisting of 17 items per-
taining to 2 domains (‘physical fatigue’, ‘cognitive fatigue’)
[35]. Physicians filled in the chart documentation form
(CDF) at inclusion including demographics, clinical MS-
characteristics, concomitant diseases, treatment with MS
drugs and antispastic drugs, mobility, treatment setting
(outpatient, inpatient rehabilitation, inpatient hospital)
and rated the severity of spasticity (mild, moderate,
severe). They also rated the global degree of spasticity
(not specified for specific muscles) using the Modified
Ashworth 5 level scale [17], the disability in EDSS [21,36],
and ADL in Barthel Index [37,38].
Statistical analysis
Data are presented as means, standard deviations (SD)
and ranges or in percentages. Spearman correlationcoefficients were conducted; and group differences were
calculated by means of the Student’s T-test, Wilcoxon-
signed-rank-test or ANOVA according to distribution of
parameter values and number of groups compared.
Patients without treatment with cannabinoid oromucosal
spray were classified as “standard group” (no changes of
patient’s status due to medication were expected be-
tween baseline and FU1). Sensitivity to change analysis
was conducted in the subgroup of patients receiving
cannabinoid oromucosal spray (“treatment group”, an
improvement of spasticity situation was expected since
they had an add-on anti-spastic therapy). The PE of the
German version of the MSSS-88 scale included testing
on data quality, scaling assumption, floor and ceiling
effects, MSSS-88 subscale inter-correlation, reliability,
construct validity and responsiveness. We used only
classical test theoretical methods to replicate the psycho-
metric characteristics of the MSSS-88 scale instead of
applying as well probabilistic methods such as the Rasch
model since a) both methods produce similar results, b)
Rasch models need large sample sizes (minimum 200),
which we did not have in our study c) Rasch models are
complicated and not widely used as mentioned as well
by the authors of the MSSS-88 [26].
Reliability
Internal consistency was estimated with Cronbach’s α
coefficient and test-retest reliability was analyzed with
Intra-Class Correlation Coefficient (ICC) between sub-
scale values at baseline and at FU1 (two-way random–ef-
fects model). The upper limit of two months for the time
period between the two visits was determined.
Construct validity
Convergent validity was calculated via correlations
between MSSS-88 subscales with corresponding sub-
scales of other PRO-instruments (MSQoL-54, EQ-5D-3L,
WEIMuS) measuring similar constructs; ‘moderate’ (r =
0.41–0.60) to 'high' correlation coefficients (r = 0.61-0.80)
(p < 0.05) were expected [39]. Discriminant validity was
investigated by correlations between MSSS-88 subscale
values with subscales of WEIMuS; low correlation coeffi-
cients were expected. Criterion validity was explored by
correlations of MSSS-88 subscale values with well-
respected outside measures (Barthel Index, Modified
Ashworth Scale, NRS spasticity and EDSS) [40]. The
goal of known groups validity analysis was to determine
whether MSSS-88 is able to detect expected differences
across patient subgroups for the following clinical
characteristics: type of spasticity, physicians’ grading of
spasticity (Modified Ashworth Scale: low [0-2] vs. high
[3,4]; severity of MS-spasticity (mild, moderate, severe)),
and patients’ grading of NRS spasticity (low [<5] vs. high
[≥5]) and sleep disturbances (low [<3] vs. high [≥3]).









n = 87 n = 36 n = 51
Socio-demographic data
Age M ± SD (range) 50.2 ± 10.4 (27-73) 51.1 ± 11.3 (27-73) 49.5 ± 9.8 (28-71)
Gender (female) n (%) 54 (62.1) 20 (55.6) 34 (66.7)
Employed* n (%) 26 (30.2)* 10 (27.8) 16 (32.0)*
Living situation*
Alone n (%) 16 (18.6) 7 (19.4) 9 (18.0)
with family/ partner n (%) 67 (77.9) 27 (75.0) 40 (80.0)
Nursing home n (%) 1 (1.2) 0 (0.0) 1 (2.0)
Other n (%) 2 (2.3) 2 (5.6) 0 (0.0)
Clinical data
Parameters physician report
Duration of multiple sclerosis in years since onset M ± SD (range) 13.6 ± 8.4* (0.2-36) 14.3 ± 8.9 (3-36) 13.1 ± 8.1* (0.2-34)
Type of multiple sclerosis
Primary progressive n (%) 16 (18.4) 7 (19.4) 9 (17.7)
Secondary progressive n (%) 44 (50.6) 15 (41.7) 29 (56.9)
Relapsing remitting n (%) 27 (31.0) 14 (38.9) 13 (25.5)
Mean number of MS relapses in the last 12 months M ± SD (range) 1.4 ± 0.7 (1-4) 1.9 ± 1.1 (2-4) 1.1 ± 0.3 (1-2)
Duration of spasticity in years since onset M ± SD (range) 8.0 ± 6.6** (0.2-27) 8.2 ± 5.6 (1.0-21) 7.9 ± 7.4** (0.2-27)
EDSS M ± SD (range) 5.7 ± 1.6 (1.5-8.5) 5.8 ± 1.7 (2.0-8.5) 5.6 ± 1.5 (1.5-8.5)
Type of spasticity (physician report)
Persistent n (%) 46 (52.9) 17 (47.2) 29 (56.9)
Paroxysmal n (%) 31 (35.6) 12 (33.3) 19 (37.2)
Both n (%) 10 (11.5) 7 (19.5) 3 (5.9)
Severity of spasticity (physician report)
mild n (%) 37 (42.5) 0 (0.0) 37 (72.5)
moderate n (%) 27 (31.0) 21 (58.3) 6 (11.8)
severe n (%) 23 (26.5) 15 (41.7) 8 (15.7)
Modified Ashworth Score M ± SD (range) 2.3 ± 1.1*** (0-4) 3.0 ± 0.8* (1-4) 1.7 ± 1.0* (0-4)
Barthel index M ± SD (range) 71.2 ± 27.5 (0-100)**** 71.0 ± 29.5 (0-100) 71.7 ± 21.6 (25-95)****
Concomitant symptoms
Fatigue n (%) 67 (77.0) 30 (83.3) 37 (72.6)
Cognitive disorder n (%) 21 (24.1) 13 (36.1) 8 (15.7)
Depressive mood n (%) 18 (20.7) 9 (25.0) 9 (17.7)
Mobility
unaided n (%) 29 (33.3) 9 (25.0) 20 (39.2)
crutches n (%) 16 (18.4) 8 (22.2) 8 (15.7)
walking frame n (%) 14 (16.1) 3 (8.3) 11 (21.6)
wheelchair n (%) 28 (32.2) 16 (44.5) 12 (23.5)
Treatment with immunomodulators in the past 12 months n (%) 18 (20.7) 20 (55.6) 43 (84.3)
Drug treatment of MS-spasticity at inclusion n (%) 57 (65.5) 27 (75.0) 30 (58.8)
Parameters patient report
Level of spasticity (NRS) M ± SD (range) 5.1 ± 2.4 (0-10) 6.5 ± 1.7 (4-10) 4.0 ± 2.3* (0-9)
Level of sleep disturbances (NRS) M ± SD (range) 3.2 ± 2.9* (0-10) 4.3 ± 3.4 (0-10) 2.4 ± 2.2 (0-8)
*1 patient with missing data; **5 patients with missing data; ***2 patients with missing data; ****38 patients with missing data.
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Responsiveness was explored by comparing the change
scores and effect sizes in the MSSS-88 subscales between
baseline and FU1 (range 2 weeks to 2 months) in two
patient groups: ‘treated’ patients and ‘standard group’. It
was expected that ‘treated’ patients would report significant
improvements across the MSSS-88 subscales (especially for
‘muscle spasm’ and ‘pain/discomfort’) and the NRS, while
no significant changes were expected in the “standard
group”. Effect size (Cohen’s d) was measured by the
standardized mean difference calculated as mean difference
between baseline and FU1 divided by the SD of the differ-
ence [41]. Effect sizes of d = 0.2 are indicating small effects,
d = 0.5 medium and d = 0.8 large effect sizes [41]. An
additional analysis was conducted with patients who were
classified as “responders”, defined as improvement ≥20% on
the patient-rated NRS scale between baseline and FU1 with
accordance to the definition applied by Novotna [20]. It
was expected that “responders” would report significantly
better values in the MSSS-88 subscales. All statistical
analyses were conducted on 0.05 significance level using
SAS version 9.2.
Results
Stage 1 (linguistic validation)
The comparison of the back-translation and the original
MSSS-88 questionnaire identified 19 items requiring refine-
ment, which were discussed with key MS opinion leaders.
From the expert discussion, 6 items (no. 13, 17, 28, 41, 55,
61) were considered as needing to be further discussed
with the patients concerning their formulation. Two CD-
sessions were conducted with 12 MS patients (9 women;
mean age 55.8 ± 12.1 years) with all types of severity and
most of them with restricted mobility. Completion time of
the German MSSS-88 was in average 20 minutes. Unclear
aspects were clarified with the developers of the MSSS-88,
e.g. “difficulties moving freely”, which was not understood
consistently by patients (possible interpretation by patients
were ‘without walking aid’, ‘unrestricted/unhindered’ or
related to ‘the distance they can walk’). The final instrument
was well accepted and understood by patients.
Stage 2 (psychometric evaluation)
Eight study centers enrolled patients; 2 centers did not par-
ticipate due to organizational reasons. In total, 90 patients
gave informed consent and participated in the period 08/
2011 to 03/2012. Valid questionnaires were available from
87 patients at inclusion, 66 patients sent their questionnaire
back at FU1. At inclusion, 36 patients (moderate: 20, severe:
16) from the MOVE2 study participated in the MSSS-88
PE and 51 patients (mild: 37, moderate: 7, severe: 7) were
recruited additionally. Socio-demographic and clinical data
are summarized in Table 1. The major part of patients was
female, had a mild form of spasticity and was outpatients.At inclusion 36 patients (41.4%) started treatment with
cannabinoid oromucosal spray.
Score distributions of the MSSS-88 at inclusion
Missing data for items of the MSSS-88 were low (range
0–5.75%); all 88 items were answered by 52 patients. Sub-
scales could be calculated for all patients indicating that
data quality was acceptable. Item means ranged from 1.43
to 3.28 and SDs from 0.68 to 1.17 (Table 2). Corrected
item-total correlations exceeded 0.40 with the vast major-
ity exceeding 0.60. Patients reported high baseline impair-
ments in the subscale ‘walking’ (65.7 ± 25.6), ‘muscle
stiffness’ (59.3 ± 25.6) and ‘body movements’ (58.8 ± 28.2).
Low floor effects were found for ‘walking’ (8.6%) and
’body movements (7.1%), indicating that some patients
reported high impairments in the respective scales, while
low ceiling effects could be demonstrated for ‘ADL’ (7.1%)
and ‘social functioning’ (7.1%), indicating that some patients
had no impairments in all aspects of the respective scales
(Table 2). Inter-correlations among MSSS-88 subscales
showed high values for ‘body movement’ and ‘walking’
(r = 0.80), for ‘social functioning’ and ‘emotional health’
(r = 0.78) as well as for ‘muscle stiffness’ and ‘muscle spasm’
(r = 0.75).
Reliability
In terms of internal consistency Cronbach’s alpha coeffi-
cients ranged from 0.92 to 0.97, and exceeded the recom-
mended minimum value of 0.70 [42] (Table 2). Cronbach’s
alpha coefficients were similar to those reported for the
original MSSS-88 [26]. For the test-retest reliability ICC
coefficients are shown in Table 2 for each subscale of 66
eligible patients who filled in the questionnaire twice. Three
of eight subscales had values over 0.7, and four subscales
had values between 0.6 and 0.7.
Construct validity
Convergent and discriminant validity
Most correlations between MSSS-88 subscales with
corresponding subscales had a magnitude and pattern
as expected (Table 3). Spearman correlations indicated
convergent validity with values ranging from r = 0.40 to
r = 0.73, with high correlations of MSSS-88 subscales with
corresponding subscales of the disease-specific MSQoL-54.
Discriminant validity could be proven by low correlations of
the MSSS-88 scales with scales of the WEIMuS Inventory.
Criterion validity
Acceptable correlations were found for the MSSS-88 sub-
scales ‘muscle stiffness’ and ‘muscle spasm’ and the global
rating of the Modified Ashworth Scale, the NRS and the
EDSS, as well as for the subscale ‘ADL’ and the Barthel
Index, the Modified Ashworth Scale, the NRS and the
Table 2 MSSS-88 score distributions and reliability [at inclusion (n = 87), and FU1 for test-retest (n = 66)]

















ICC*** (n = 66)
Muscle Stiffness 12 2.09 - 3.07 0.82 - 1.04 0.67 - 0.83 59.3 ± 25.6 (5.6 – 100.0) 2.3 0.0 0.95 0.95 0.74
Pain and Discomfort 9 1.90 - 2.66 0.91 - 1.10 0.55 - 0.81 43.3 ± 26.7 (0.0 – 100.0) 1.2 2.4 0.92 0.95 0.67
Muscle Spasms 14 1.43 - 2.61 0.68 - 1.15 0.42 - 0.75 39.6 ± 23.9 (0.0 – 92.3) 0.0 2.3 0.92 0.93 0.47
Activities of Daily Living 11 2.16 - 2.74 1.03 - 1.17 0.81 – 0.90 47.1 ± 31.8 (0.0 – 100.0) 6.0 7.1 0.97 0.95 0.87
Walking 10 2.82 - 3.21 0.83 - 1.02 0.63 - 0.87 65.7 ± 25.6 (13.3 – 100.0) 8.6 0.0 0.95 0.96 0.67
Body Movements 11 2.46 - 3.28 0.83 - 1.11 0.78 - 0.87 58.8 ± 28.2 (6.1 – 100.0) 7.1 0.0 0.96 0.96 0.72
Emotional Health 13 1.54 - 2.36 0.77 - 1.04 0.69 - 0.84 34.1 ± 25.6 (0.0 – 94.9) 0.0 1.2 0.95 0.96 0.61
Social Functioning 8 1.74 - 2.63 0.87 - 1.09 0.66 - 0.84 36.6 ± 28.1 (0.0 – 100.0) 1.2 7.1 0.94 0.95 0.62
*Ceiling and floor effects are the percent of people scoring the best (ceiling, score = 0) or worst (floor, score = 100) possible.
**Hobart et al. [26].
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(Table 4).
Known groups’ validity
Significant differences were found between patients with low
vs. high self-reported NRS spasticity (Figure 1); patients with
high NRS spasticity reported higher impairments in all
MSSS-88 subscales. The same pattern was shown for the
self-reported level of sleeping disturbances (data not shown).
Concerning the severity of spasticity, significant differ-
ences between patients with mild, moderate or severe
spasticity could be recorded for all subscales of the MSSS-
88 except for ‘emotional health’ (Figure 2).
Patients with high increase of muscle tone (grade 3-4 on
the modified Ashworth scale) reported higher impair-
ments in almost all MSSS-88 subscales compared to pa-
tients with no or low increase of muscle tonus (grade 0-2),
except for ‘emotional health’ (Table 5). For type of spasti-
city, significant differences were found. Patients with both
types of spasticity (persistent, paroxysmal) reported higher
impairments in five of the MSSS-88 subscales, except for
‘pain/discomfort’, ‘walking’ and ‘body movement’ (Table 5).
Responsiveness
Responsiveness was explored in a total of 66 people: 24
treated with cannabinoid spray (“treated group”), 42 people
not treated (“standard group”). As predicted, change of












MSQoL-54 Physical health 0.52
Activities of Daily Living
EQ-5D Usual activity 0.68
MSQoL-54 Physical health 0.71
Walking
EQ-5D Mobility 0.44
MSQoL-54 Physical health 0.68
Body Movements
EQ-5D Mobility 0.59







WEIMuS Cognitive Fatigue 0.58
MSQoL-54 Social function 0.61
Spearman correlation between MSSS-88 subscales and corresponding subscales ofthe treated than the standard group (Table 6). In the treated
group significant changes with a moderate effect size were
found for ‘muscle spasms’, ‘emotional health’ and ‘pain/
discomfort’; same was found for the NRS. In the standard
group, no significant changes could be detected in the NRS
spasticity scale or in any MSSS-88 subscale. Therefore,
sensitivity to change of the MSSS-88 scale could be
demonstrated.
Discussion
The linguistic validation and cross-cultural adaptation of the
English MSSS-88 questionnaire into German underwent
forward/backward translations, reconciliation, discussion
with clinical MS-experts, CD with MS patients and psycho-
metric testing of the MSSS-88 questionnaire in MS patients
with different severities of spasticity as required by pub-
lished guidelines for translations of PRO instruments [43].
Floor effects were found for the subscales ‘walking’ and
‘body movements’, indicating that patients reported very
high impairments in these subscales. Internal consistency
showed values for all subscales above Cronbach’s α = 0.90,
mirroring the results from the original data, and high ICCs
were found for re-test reliability testing after 1 month
follow-up for all subscales above r = 0.61, except for ‘muscle
spasm’. Convergent validity was proven, with acceptable
correlations with the generic EQ-5D-3L questionnaire) and
good correlations for the disease-specific MSQoL-54






WEIMuS Cognitive fatigue 0.28
WEIMuS Cognitive fatigue 0.44
WEIMuS Cognitive fatigue 0.26
WEIMuS Cognitive fatigue 0.25
WEIMuS Physical fatigue 0.34
WEIMuS Cognitive fatigue 0.26
other patient-reported instruments.








Muscle Stiffness 0.52 0.45 0.53 0.45
Pain and Discomfort 0.26 0.14 0.52 0.27
Muscle Spasms 0.50 0.47 0.63 0.50
Activities of Daily Living 0.58 0.82 0.56 0.64
Walking 0.35 0.56 0.38 0.44
Body Movements 0.53 0.66 0.51 0.55
Emotional Health 0.24 0.09 0.36 0.12
Social Functioning 0.29 0.30 0.48 0.37
Spearman Correlations with Modified Ashworth Scale, Barthel Index, NRS
spasticity and EDSS measures.
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Inventory. The MSSS-88 could significantly discriminate
between clinical subgroups of spasticity both for self-rated
(NRS assessment) and physician-rated severity. A higher
impairment could be demonstrated in those patients suffer-
ing from both types of spasticity - persistent and paroxys-
mal. Sensitivity to change could be proven for ‘treated’
patients using the cannabinoid oromucosal spray in four
out of eight MSSS-88 subscales (‘muscle spasm’, ‘emotional
health’, ‘pain/discomfort’ and ‘body movement’). This reduc-
tion was mirrored by the difference in the self-rated severity
of spasticity (p = 0.0078). By contrast, no significant differ-
ence could be found in the ‘standard group’ not using
treatment. It should be mentioned that patients treated
with cannabinoid oromucosal spray had at inclusion already
higher impairments in the subscale ‘muscle stiffness’ com-
pared to patients in the untreated group, which can beFigure 1 Mean MSSS-88 subscale score for people with high (NRS ≥ 5
NRS: numerical rating scale (0 – 10).explained with the requirements of treatment using canna-
binoid oromucosal spray only in patients with moderate to
severe spasticity. Furthermore in the group of untreated
patients 72.5% had mild spasticity at inclusion compared to
none of the patients in the treated group, while 41.7% of
the treated group suffered from severe spasticity compared
to only 15.7% in the untreated group.
The German MS patients were comparable to the
original English study sample in terms of demographic
characteristics (mean age 50 vs. 54 years, female 62% vs.
63%). By contrast, they differed related to clinical data
(duration of MS from onset 13 vs. 21 years, unaided
walking 33% vs. 5.4%, Mean Modified Ashworth score 2 vs.
0.95). In the German study, spasticity was assessed globally
by means of the Modified Ashworth Scale, not specific for
different muscles, while in the original CAMS study, spasti-
city was assessed across 20 muscles by means of the Modi-
fied Ashworth Scale. In attempting to compare our findings
for the Modified Ashworth Scale with the original data of
the CAMS study, where data were derived in different
ways, we divided the mean value of the Modified Ashworth
scale of (M= 19) by 20 based on the algorithm used in the
CAMS study, with a possible range of 0-80 (compared to
the range of the Modified Ashworth Scale of 0-4 in the
German cohort). As one would expect, the findings in the
CAMS study are lower in the Modified Ashworth scale
than the German MOVE2 study, since here an unspecified
global assessment of spasticity was done. Moreover, it
should be taken into consideration for the interpretation of
the results that the (Modified) Ashworth Scale has been
demonstrated not to be a valid and reliable instrument for
the assessment of the degree of spasticity [44,45]. PROs, n = 54) and low (NRS < 5, n = 32) self-reported NRS spasticity.
Figure 2 Mean MSSS-88 subscale score for people with mild (n = 37), moderate (n = 25), or severe spasticity (n = 23) [rated by physician].
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measures comprising the impact of the disease or the
treatment on different aspects of life [46] and therefore
should not only be implemented in clinical trials, but also
in routine care [47]. Depending on the purpose of a spe-
cific study or the needs of PRO assessment in routine care,
the MSSS-88 scale can be used together with other instru-
ments assessing different aspects important for patients
with MS, such as self management [48], functioning [37]
and fatigue [35].
A limitation of this validation study might be the rela-
tively low number of enrolled patients (n = 87) for the psy-
chometric testing of the newly-translated MSSS-88
questionnaire. This is partly due to the fact that from the
initially planned ten study centers two did not participate in
the study because of organizational reasons. Unfortunately
not all participating patients filled in the re-testTable 5 Known groups' validity of the MSSS-88 [at inclusion (
Subscale MSSS-88
Type of spasticity (physician asse
Persistent Paroxysmal both
(n = 46) (n = 31) (n = 10)
n Mean ± SD n Mean ± SD n Mea
Muscle Stiffness 44 53.85 ± 24.96 30 57.85 ± 25.13 10 81.5
Pain and Discomfort 43 40.35 ± 23.57 29 40.63 ± 29.40 10 58.1
Muscle Spasms 45 34.47 ± 20.56 30 40.70 ± 26.51 10 56.9
Activities of Daily Living 44 44.20 ± 28.82 28 42.53 ± 34.60 10 70.9
Walking 39 64.87 ± 24.16 23 60.74 ± 28.38 6 81.6
Body Movements 45 55.70 ± 25.68 28 56.17 ± 32.13 9 79.4
Emotional Health 45 31.15 ± 22.90 30 32.65 ± 26.31 9 53.5
Social Functioning 43 34.55 ± 25.96 30 32.60 ± 27.39 10 56.6
Mean MSSS-88 subscale scores for type of spasticity and muscle tonus [rated by phquestionnaire (n = 66): from those 36 patients starting to
use cannabinoid oromucosal spray at inclusion, only 24 pa-
tients filled in the re-test of the MSSS-88 questionnaire. In
the current study, we did not evaluate the measurement
equivalence, due to two reasons. First, the number of
enrolled patients was relatively low, so that we could not
do these analyses and second the aim of this paper was the
linguistic and psychometric validation of the newly trans-
lated MSSS-88. Without this measurement, a meaningful
comparison of results across countries is difficult [43]. In
general, we would recommend testing measurement
equivalence, which is defined as “whether or not, under dif-
ferent conditions of observing and studying phenomena,
measurement operations yield measures of the same attri-
bute” [49], if testing of cross-cultural differences is intended.
Although the number of enrolled patients (n = 87) was
lower than expected, the response rate was higher (87%)n = 87)]
ssment) Modified Ashworth scale value group(physician assessment)
p-value
0 to 2 3 to 4
p-value(n = 48) (n = 37)
n ± SD n Mean ± SD n Mean ± SD
0 ± 16.45 0.0067 48 46.98 ± 24.25 36 74.03 ± 17.81 <0.0001
5 ± 27.83 0.1434 47 36.84 ± 26.54 35 50.39 ± 24.95 0.0215
0 ± 24.40 0.0243 48 29.09 ± 21.24 37 52.57 ± 20.96 <0.0001
1 ± 27.37 0.0351 47 32.03 ± 28.32 35 66.84 ± 24.38 <0.0001
7 ± 20.30 0.2068 46 57.91 ± 25.99 22 79.70 ± 17.70 0.0007
6 ± 21.84 0.0608 48 46.79 ± 27.31 34 74.96 ± 20.83 <0.0001
6 ± 28.48 0.0481 48 30.49 ± 25.31 36 38.89 ± 25.04 0.1343
7 ± 30.63 0.0459 47 29.37 ± 26.45 36 45.83 ± 26.98 0.0066
ysician].
Table 6 Responsiveness (MSSS-88, NRS)
MSSS-88 Subscale Patients treated with cannabinoid oromucosal spray (n = 24) Patients not treated with cannabinoid oromucosal spray (n = 42)
n Baseline Follow-Up Change baseline to Follow-up n Baseline Follow-Up Change baseline to Follow-up
M ± SD M ± SD Mean Difference (SD) p- value+ Cohen d M ± SD M ± SD Mean Difference (SD) p- value+ Cohen d
Muscle Stiffness 22 76.55 ± 17.58 70.74 ± 14.25 -5.81 (15.08) 0.0852 0.39 42 48.74 ± 24.60 48.45 ± 19.88 -0.28 (16.92) 0.9143 0.02
Pain and Discomfort 21 56.97 ± 27.25 46.80 ± 22.74 -10.16 (19.97) 0.0302 0.51 42 34.87 ± 24.36 35.98 ± 20.84 1.11 (17.80) 0.6873 0.06
Muscle Spasms 23 56.48 ± 18.21 41.69 ± 14.04 -14.79 (22.45) 0.0045 0.66 41 32.20 ± 21.47 29.97 ± 17.11 -2.23 (17.49) 0.4189 0.13
Activities of Daily Living 24 67.30 ± 26.55 66.49 ± 26.15 -0.80 (12.65) 0.7581 0.06 38 34.99 ± 30.53 34.94 ± 26.98 -0.06 (17.05) 0.9840 0.00
Walking 15 72.44 ± 21.10 68.67 ± 21.63 -3.78 (20.47) 0.4864 0.18 38 60.10 ± 27.02) 59.47 ± 28.45 -0.62 (21.07) 0.8562 0.03
Body Movements 22 74.10 ± 22.20 66.36 ± 22.23 -7.74 (17.01) 0.0446 0.46 41 49.31 ± 28.93 45.97 ± 24.53 -3.33 (20.39) 0.3014 0.16
Emotional Health 22 43.50 ± 24.11 32.05 ± 23.84 -11.45 (22.30) 0.0253 0.51 42 30.43 ± 25.26 28.33 ± 24.92 -2.11 (19.49) 0.4876 0.11
Social Functioning 22 49.51 ± 28.48 41.72 ± 24.42 -7.79 (18.97) 0.0677 0.41 41 30.05 ± 25.27 29.81 ± 22.41 -0.25 (23.15) 0.9459 0.01
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scale (78%) [26], where in total 259 patients were enrolled.
Since the psychometric characteristics of the original
MSSS-88 scale could already be clearly and homogenously
verified in this relatively limited cohort of MS patients, we
do not expect differences in a bigger cohort and therefore
would like to apply our findings to the German MS-
population. Moreover, Hobart published recently an esti-
mation of necessary sample size for reliability and validity
testing in neurology and concluded that reliability estimates
are stable in magnitude in sample sizes of a minimum of
20, and validity estimates are stable in samples of n ≥ 80
[50], which confirms our interpretation that our results can
be generalized.
Conclusion
This new translation of the MSSS-88 questionnaire into
German was easily understood by MS patients and proven
to be a reliable and valid instrument for the assessment of
the impact of spasticity on MS patients. It showed excellent
psychometric characteristics - similar to the original English
instrument - although its measurement equivalence could
not be tested in the frame of the current study. Moreover, it
could be shown that the new instrument is sensitive to
changes and therefore it can be administered in clinical
trials aiming to track the evolution of MS-spasticity.
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